Literature DB >> 32941593

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.

Marco Falcone1, Giusy Tiseo1, Manuela Nicastro2, Alessandro Leonildi3, Alessandra Vecchione3, Costanza Casella2, Francesco Forfori2,4, Paolo Malacarne2, Fabio Guarracino2, Simona Barnini3, Francesco Menichetti1.   

Abstract

Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990Acinetobacter baumanniizzm321990; ICU; NDM-producing Klebsiella pneumoniaezzm321990; cefiderocol; metallo-β-lactamases

Year:  2021        PMID： 32941593     DOI： 10.1093/cid/ciaa1410

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  25 in total

Review 1.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

2.  Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study).

Authors:  Marco Falcone; Lorenzo Roberto Suardi; Giusy Tiseo; Valentina Galfo; Sara Occhineri; Stefano Verdenelli; Giancarlo Ceccarelli; Melita Poli; Marco Merli; Davide Bavaro; Anna Carretta; Giuseppe Nunnari; Emmanuele Venanzi Rullo; Enrico Maria Trecarichi; Chiara Papalini; Antonina Franco; Rosa Fontana Del Vecchio; Vincenzo Bianco; Rodolfo Punzi; Daniela Francisci; Raffaella Rubino; Carlo Torti; Massimo Puoti; Sergio Carbonara; Antonio Cascio; Annalisa Saracino; Teresa Santantonio; Mario Venditti; Francesco Menichetti
Journal:  JAC Antimicrob Resist       Date:  2022-06-16

Review 3.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

4.  Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Marco Falcone; Giusy Tiseo; Alessandro Leonildi; Leonardo Della Sala; Alessandra Vecchione; Simona Barnini; Alessio Farcomeni; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

Review 5.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

6.  Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.

Authors:  Nathaniel C Warner; Luther A Bartelt; Anne M Lachiewicz; Kathleen M Tompkins; Melissa B Miller; Kevin Alby; Melissa B Jones; Amy L Carr; Jose Alexander; Andrew B Gainey; Robert Daniels; Anna-Kathryn Burch; David E Brown; Michael J Brownstein; Faiqa Cheema; Kristin E Linder; Ryan K Shields; Sarah Longworth; David van Duin
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

7.  Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.

Authors:  Noor Zaidan; J Patrik Hornak; David Reynoso
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

8.  Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance.

Authors:  Christina König; Anna Both; Holger Rohde; Stefan Kluge; Otto R Frey; Anka C Röhr; Dominic Wichmann
Journal:  Antibiotics (Basel)       Date:  2021-05-28

9.  Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3.

Authors:  Giusy Tiseo; Marco Falcone; Alessandro Leonildi; Cesira Giordano; Simona Barnini; Gabriele Arcari; Alessandra Carattoli; Francesco Menichetti
Journal:  Open Forum Infect Dis       Date:  2021-03-20       Impact factor: 3.835

10.  Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives.

Authors:  Davide Fiore Bavaro; Alessandra Belati; Lucia Diella; Monica Stufano; Federica Romanelli; Luca Scalone; Stefania Stolfa; Luigi Ronga; Leonarda Maurmo; Maria Dell'Aera; Adriana Mosca; Lidia Dalfino; Salvatore Grasso; Annalisa Saracino
Journal:  Antibiotics (Basel)       Date:  2021-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.